Evaluating the Role and Efficacy of Cobenfy (Xanomeline and Trospium Chloride) in Schizophrenia Treatment - review

Abstract

Schizophrenia is a complex psychiatric disorder often resistant to dopamine-targeting antipsychotics. Cobenfy, a combination of xanomeline and trospium chloride, offers a novel approach by modulating muscarinic receptors while minimizing side effects. This review evaluates its efficacy and safety, particularly in treatment-resistant cases. Clinical trials show significant reductions in both positive and negative symptoms, positioning Cobenfy as a promising alternative.

Keywords

• Cobenfy
• xanomeline-trospium
• muscarinic receptor modulation
• schizophrenia treatment
• non-dopaminergic antipsychotics
• EMERGENT trials